Jamba, Inc. (JMBA): Is This Stock Destined for Greatness?

It seems like Jamba may need the help, as its most recent earnings were a bit flatter than expected. Overall sales are growing, but very modestly, which makes it difficult to project similar growth to what we’ve seen in the graphs above. Still, it’s possible that a strong summer sales season will outweigh the cold-weather weakness, and Jamba might move into profitable territory for the first time ever. The company is pushing hard to expand self-serve JambaGO stations into schools and other captive environments, which could provide a steadier stream of revenue over retail outlets that have to generate interest from afar. Jamba isn’t ignoring its retail storefronts, though — earlier this year, the company fired a healthy broadside at kids’ meal leader McDonald’s Corporation (NYSE:MCD) with a chainwide rollout of Jamba Kids Meals. Granted, a burger and fries with a toy are more fun than a smoothie and a sticker, but there are plenty of yuppie parents who will appreciate the alternative, even if their children won’t.

Putting the pieces together
Today, Jamba has some of the qualities that make up a great stock, but no stock is truly perfect. Digging deeper can help you uncover the answers you need to make a great buy — or to stay away from a stock that’s going nowhere.

The article Is Jamba’s Stock Destined for Greatness? originally appeared on Fool.com.

Fool contributor Alex Planes has no position in any stocks mentioned. The Motley Fool recommends and owns shares of McDonald’s, Monster Beverage, and Starbucks.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!